DiaMedica Inc. (TSX-V:DMA) is a biotechnology company developing first-in-class treatments for the treatment of diabetes.
DiaMedica's lead compound, DM-199, is a recombinant human protein for the treatment of both Type 1 and Type 2 diabetes and their complications.
The Company is also developing the first therapeutic GPCR agonist monoclonal antibody, DM-204, for the treatment of Type 2 diabetes and cardiovascular disease.
DiaMedica’s shares trade on the Toronto Stock Exchange Venture (TSXV: DMA). For more information please visit www.diamedica.com.